Wells Fargo analyst Tiago Fauth raised the firm’s price target on United Therapeutics to $350 from $325 and keeps an Overweight rating on the shares. Survey of 50 docs who treat on average of 87 PAH patients annually reaffirms the firm’s view that tailwinds in PH-ILD should more than offset potential headwinds in PAH. Wells continues to the like the setup for shares through 2024 and into 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- Biotech Alert: Searches spiking for these stocks today
- Liquidia says court denies motion for preliminary injunction filed by United Therapeutics
- United Therapeutics price target raised to $400 from $375 at Oppenheimer
- United Therapeutics reports Q1 EPS $6.17, consensus $5.65
- United Therapeutics Corp. (UTHR) Q1 Earnings Cheat Sheet